Zacks Industry Outlook Medical Systems, American Well and Butterfly Network

Zacks identifies Inspire Medical Systems, American Well and Butterfly Network as potential beneficiaries of expanding AI-enabled healthcare and digital-care adoption, with the AI-in-healthcare market projected to grow at a 39.7% CAGR through 2031. American Well and Butterfly Network are forecast to grow 2026 earnings by 52.7% and 25.0%, respectively, versus 15.3% for the industry, while Inspire holds a Zacks Rank #1 and AMWL and BFLY hold Rank #2 ratings. The Medical Info Systems group has nevertheless fallen 16% over the past year, underperforming the S&P 500's 16.8% gain, and trades at 5.76x forward sales versus 4.67x for the S&P 500 amid heightened cybersecurity and AI-governance risks.

Analysis

The actionable implication is not broad exposure to “healthcare AI,” but dispersion between workflow owners and feature vendors. ORCL can monetize agentic functionality through its installed EHR base and potentially raise switching costs, creating a near-term competitive headwind for standalone virtual-care infrastructure such as AMWL unless it can demonstrate that its platform remains payer- and EHR-agnostic. The first evidence to watch over the next 1-3 quarters is net revenue retention, bookings duration and implementation margins—not AI product announcements.

INSP is only indirectly exposed to healthcare IT enthusiasm: its valuation and earnings path remain primarily governed by OSA referral throughput, implant volumes, reimbursement and sales-force productivity. Any AI-related rerating is therefore vulnerable to reversal if procedure growth misses, but improved diagnostic identification and referral routing could become a 6-18 month demand tailwind. BFLY has a more credible software optionality, yet the key question is whether AI software converts into recurring enterprise revenue rather than subsidizing hardware placements; contract value, attach rate and gross-margin progression are the required proof points.

The contrarian view is that elevated sector sales multiples already price a substantial portion of the digital-health recovery while cybersecurity and AI-governance requirements raise implementation costs and lengthen hospital procurement cycles. Cyber incidents are more likely to favor scaled incumbents with security budgets and embedded data integrations—ORCL and potentially OMCL—than smaller vendors. This is a selective earnings-quality trade, not a catalyst for a broad medical-information-systems long.

Near term, the promotional source and lack of new company-specific operating data argue against chasing the named small/mid-cap names on this item alone. A risk-on move in unprofitable growth/AI equities could lift AMWL and BFLY mechanically in days; over months, cash burn, customer concentration and conversion of bookings to revenue should dominate. The thesis is falsified if AMWL shows accelerating subscription retention and positive operating leverage, or if BFLY discloses material high-margin software penetration ahead of expectations.

Key Decisions for Investors

• Maintain or initiate a 6-12 month long ORCL / short AMWL pair, sized beta-neutral: ORCL has stronger distribution and data-integration leverage, while AMWL must prove differentiated economics against platform consolidation. Review if AMWL reports sustained net-revenue-retention acceleration, material multi-year government wins, or clear EBITDA inflection.
• Keep INSP on a fundamental long watchlist rather than buy on AI framing; enter only following evidence of procedure-volume reacceleration and maintained gross-margin guidance. Target a 6-18 month thesis around referral and reimbursement execution; exit on a material cut to implant-volume outlook or adverse reimbursement signal.
• Treat BFLY as a tactical, high-volatility watch item, not a core AI long. Upgrade only after disclosed software/AI attach-rate and recurring-contract-value data establish that enterprise software is expanding gross margin; absent that, hardware-led revenue and cash usage remain dominant risks.
• Avoid broad long exposure to the medical-information-systems basket at current premium sales valuations. If seeking a cybersecurity spillover expression, favor scaled healthcare workflow incumbents such as ORCL or OMCL over smaller digital-health vendors until procurement-cycle and security-cost impacts are visible in quarterly results.